ReviewJournal of gynecologic oncology2022

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).

Hiroshi Asano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.